Compare BridgeBio Pharma Inc (BBIO) vs Rush Street Interactive Inc (RSI) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Rush Street Interactive (RSI) trades at $24.88, down 0.8% with strong technical momentum indicators showing oversold conditions (RSI at 16-17). The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Analyst consensus remains strongly bullish with 10 buy ratings and a $34.75 price target representing 40% upside potential.

RSI demonstrates robust revenue growth and expanding market presence but faces valuation concerns with a high P/E of 80.26. Key risks include competitive pressures in online gambling and regulatory uncertainties. The combination of strong fundamentals, positive analyst sentiment, and oversold technical conditions suggests potential for near-term recovery.